文献速递艾滋病与性传播感染

利匹韦林联合考比司他增强达芦那韦作为HIV感染者双药转换方案:随机对照非劣效性试验(PROBE 2)

Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2).
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

第24周双药组90.0% vs 继续组93.8%维持病毒学抑制,差异-3.75%(95%CI -11.63~5.63),证实非劣效性。双药方案病毒学有效且可能避免NRTI毒性。

要点

  • 转换双药方案第24周病毒学抑制率90.0%,非劣效于继续三联ART(93.8%)。
  • 双药组无HIV-RNA>50 copies/mL事件,继续组3.7%。
  • 双药组骨硬度中位数上升,继续组显著下降(P=0.043)。

核心结论

  • 每日一次利匹韦林联合考比司他增强达芦那韦是有效的双药方案,兼具高病毒学疗效和避免主要NRTI毒性的潜力。

研究设计与样本

  • 主要终点为第24周HIV-RNA<50 copies/mL的受试者比例(快照算法),非劣效界值-12%。

主要发现

  • 第24周双药组72例(90.0%)和继续组75例(93.8%)维持HIV-RNA<50 copies/mL,差异-3.75%(95%CI -11.63~5.63),确认非劣效性。
  • HIV-RNA>50 copies/mL:双药组0%,继续组3.7%(95%CI -0.4~7.9),亦确认非劣效性。
  • 双药组4例报告不良事件但未导致停药(双药组1例,继续组3例);双药组8例停药,继续组3例。
  • 双药组血脂升高,但仅在含替诺福韦二吡呋酯的继续组和转换前含替诺福韦二吡呋酯的双药组中差异有统计学意义。
  • 继续组骨硬度中位数从86.1 g/cm2(IQR 74-98)降至83.2 g/cm2(IQR 74-97),组内下降显著(P=0.043);双药组从84.9 g/cm2(IQR 74-103)升至85.5 g/cm2(IQR 74-101)。

临床怎么用

  • 对于稳定三联ART且病毒学抑制的HIV感染者,可考虑转换为利匹韦林+考比司他增强达芦那韦双药方案。
  • 转换前需评估NRTI相关毒性风险,双药方案可能有助于避免骨密度下降等NRTI毒性。

局限性

  • 开放标签设计。
  • 随访至第24周,长期数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We explored the combination of rilpivirine plus cobicistat-boosted darunavir [a two-drug regimen (2DR)] when switching from standard triple combined ART. METHODS: In this randomized, open-label, non-inferiority trial, participants had an HIV-RNA <50 copies/mL on a stable (>6 months) three-drug regimen. The primary endpoint was proportion with HIV-RNA <50 copies/mL at Week 24 (snapshot algorithm), with a -12% non-inferiority margin. ClinicalTrials.gov: NCT04064632. RESULTS: One hundred and sixty patients were allocated (1:1) to 2DR or to continue current ART (CAR). At Week 24, 72 (90.0%) of participants with 2DR and 75 (93.8%) with CAR maintained HIV-RNA <50 copies/mL [difference -3.75% (95% CI = -11.63 to 5.63)], confirming non-inferiority. Non-inferiority was confirmed considering an HIV-RNA >50 copies/mL (0% for 2DR; 3.7% for CAR; 95% CI = -0.4 to 7.9). Four patients reported adverse events not leading to treatment discontinuation (one patient in the 2DR group and three patients in the CAR group); eight subjects discontinued therapy in the 2DR group and three in the CAR group. With 2DR, lipid serum concentrations increased, but differences were statistically significant only for tenofovir disoproxil fumarate-containing CAR and in 2DR patients receiving a pre-switch regimen including tenofovir disoproxil fumarate. Median bone stiffness decreased in the CAR group from 86.1 g/cm2 (IQR = 74-98) to 83.2 g/cm2 (IQR = 74-97) and increased in the 2DR group from 84.9 g/cm2 (IQR = 74-103) to 85.5 g/cm2 (IQR = 74-101). The reduction within the CAR group was significant (P = 0.043). CONCLUSIONS: Once-daily rilpivirine plus cobicistat-boosted darunavir is an effective 2DR that combines a high virological efficacy with a potential to avoid major NRTI toxicities.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Maggiolo F, Gianotti N, Comi L, et al. Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2). J Antimicrob Chemother. 2020. PMID: 32129855. doi:10.1093/jac/dkaa018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。